A private message/response in my inbox for any interestedI would like to share a direct message exchange I had here in Stockhouse for anybody interested. I edited out some content to protect the privacy. From: [deleted] Date: 5/16/2019 4:07:35 PM Subject: Upcmoing Rights Offering Hello C.C. I'm sorry to just direct message you out of the blue however I am having trouble finding the answers I need to make an informed decision with re: the upcoming rights offering. If I was able to get the full 20:1 I could lower my ACB to approx $[deleted]/share and and would obviously stand a way better chance at recovering lost $$$. The answers I'm having trouble finding answers to are the following; 1. Following the CRL from the FDA, what are the chances that Ryplazim will get approved if CMC changes are all that stand in the way? 2. Why would a company that was on the verge of bankruptcy pursue a Nasdaq listing? One would think they would get destroyed on the U.S. market for the past few years of lack of generating any meaningful revenue. 3. What are your thoughts on the current direction of the plasma and small molecule segments of their business? Are these guys finally on the right track or headed in the same direction of past management? 4. Even if Lazard does produce 2 deals in H2 of 2019, what sort of valuation could someone ascribe to PLI? obviously it depends on the terms of the deals but in your opinion would the market return to Prometic with a sign of optimism or are we beating a dead horse here? I guess in the simplest terms is if you were in my position (significant losses but have time to wait it out) is there any reason to pursue this any further ?(science, change of direction, potential partners, Nasdaq Listing, 86 % ownership with SALP) One thing that baffles me is why Thomvest would continue dumping money in IF they did not think there was a payday down the road! I know that this was a long drawn out e-mail and would include speculation, opinion and would be subjective but I really appreciate your time and thoughts on the matter. Thank you for your time! [deleted for privacy] To: [deleted for privacy] Date: 5/16/2019 7:07:26 PM Subject: RE:Upcmoing Rights Offering Hi [deleted], I'll do my best to answer your questions. However, please note that they are my opinions. You should not let them unduly influence your own insights and due diligence. (In other words, you are totally responsible for your own investment decision). 1. We don't know if Prometic has successfully addressed their CMC requirements as indicated in the FDA's CRL. Recently a British company received their second CRL for the CMC problems. https://www.fiercebiotech.com/biotech/acacia-gets-second-fda-rejection-as-manufacturing-fault-drags? However, in that case, it's the contract manufacturer who could not correct the CMC problems, not the drug developer or their clinical and non clinical data. It is possible that Prometic, having taken so long, has indeed fixed the CMC part of the BLA. If so, then I expect the chance of approval being good. If not, then, a second CRL is not impossible. 2. For clinical stage or early commercial stage biotech companies in the US, no significant revenue is not uncommon. Other factors such as the pipeline, the partnership, the indications' market potential etc. play important roles too. Health care sector (which biotech stocks are a part of) is a big sector that commands a lot of capital (e.g. investors of all sizes are in this space). It seems to me that in the US, biotech stocks attract a lot MORE investment interest than in Canada. A company like Prometic, with somewhat competitive pipe line but weak finances/management, may be ok on Nasdaq, provided that the finances and the management improve of course. The lack of revenue alone is not a deal breaker, imo, but (continuing) poor finances/management or trial failures will be. 3. per April 1 Q1 report, it seems to me that PLI wants to focus on small molecules more and let a partner takes over plasminogen' sale and perhaps further partnership for other plasma proteins. I think that this is a good move. However, 4050's p2 trials in NASH, IPF and a kidney indication will take at least 1-2 year or longer to complete and 4547 only start at phase 1, so at least 3-4 year before enough data is generated for partnerships talks. You need to consider your own time frame for these (potentially positive) developments to come into fruition. 4. If Lazard does close 2 deals in H2 2019, I estimate that it would be a very positive value driver for the stock. They will not only provide much-needed cash, but more importantly they will serve as a validation of PLI's drug candidates/the company by the pharma industry. Companies like FGEN, GLPG both have big partners for some of their drug candidates. They are both multi-$B cap clinical stage biotech without any approved drugs (therefore no revenues except equity offers and upfront/license money from partners). FGEN has >$700M usd, and GLPG has >$1B euro in cash position currently. I think that TV does want develop Prometic as a successful drug developer/pharma and they do believe in the potential of this company, although even for them, there is no risk-free investment (i.e. there is no certainty of a future success). I think that if you have time and am able to achieve a $[deleted] ([delted]times 1.521 cents) by buying the rights offer, it's a tolerable risk, imo, provided that you don't have other biotech investments that have better risk/reward. You will break even when the market cap of Prometic reaches C$[deleted]B, which is achievable in the next 2-3 years, imo, if the company can succeed in some or all the positive developments (e.g. deals, BLA re-submission/approval, 4050/4547 trials, nasdaq listing, better burn rate, better finances etc.). However, as this is a highly speculative and risky investment, I would say that your position should not exceed your risk tolerance (e.g. not your only investment, not money that you will need in a hurry, not money that you cannot afford to lose completely etc.). Hope that this is clear and somewhat useful for your consideration. All the best, CC